Improving the Uptake of Transcatheter aortic valve replacement (TAVR)
Transcatheter aortic valve replacement (TAVR), with comparable benefits and lower risks of complications compared to surgical aortic valve replacement (SAVR), is the preferred therapy in high-risk patients with severe aortic stenosis and patients not eligible for surgery (Nishimura et al.,2017). With evidence supporting its use and benefits in patients with low- surgical risk (Kolte et al., 2019) and intermediate-surgical risk (Smith et al., 2016). However, despite the current cardiovascular guidelines, there are variations in the proportion of patients undergoing TAVR compared to SAVR across some hospitals in Ontario (Asgar et al., 2019). This Capstone project aims to:
1. To understand the principle reasons why SAVR is being chosen over TAVR; and
2. To develop an evidence-based strategy to promote TAVR as the Standard of Care.
Capstone Advisory Committee:
TRP Faculty Lead:
Dr. Joseph Ferenbok